{
  "document_id": "RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement",
  "file_path": "data/CUAD_v1/full_contract_pdf/Part_I/Development/RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement.pdf",
  "text_length": 266122,
  "chunk_count": 362,
  "vector_store_path": "output/vector_stores/RevolutionMedicinesInc_20200117_S-1_EX-10.1_11948417_EX-10.1_Development Agreement",
  "summary": "obligation will submit a confidential treatment request and a proposed redacted version of this Agreement as part of such draft. Such draft securities\nfiling will, where possible, be provided to the other Party reasonably in advance of the deadline for such securities filing, and the other Party agrees to\npromptly (and in any event, no less than [***] (or such shorter time to meet any filing deadline where it was not possible to provide the other Party with\n[***] notice) after receipt of such confidential treatment request and proposed redactions) give its input in a reasonable manner in order to allow the\nParty seeking disclosure to file its request within the timelines proscribed by the regulations of applicable Governmental Authorities or securities\nexchange. The Party seeking such disclosure will use reasonable efforts to obtain confidential treatment of this Agreement from the applicable\n\n(ii) as provided in this Section 11.5 or as otherwise provided in this Agreement or any Ancillary Agreement or with the prior express written permission of\nthe other Party, except as may be required by Applicable Law.\n(b) If a Party is required by Applicable Law, rule or regulation to make a securities filing relating to the signing or effectiveness of this Agreement,\nor to the terms of this Agreement, with the appropriate Governmental Authorities (including the U.S. Securities and Exchange Commission, and any\nsecurities exchange on which securities of such Party are listed), then the Party under such requirement will prepare a draft of such securities filing for\nreview and comment by the other Party. If such securities filing includes the disclosure of this Agreement and its terms, the Party under such disclosure\nobligation will submit a confidential treatment request and a proposed redacted version of this Agreement as part of such draft. Such draft securities\n\n1.131  In addition to the foregoing definitions, the following table identifies the location of the following definitions set forth in various other\nSections of, or Exhibits to, the Agreement:\nDefined Term Section\nAcquiror Section 15.2(a)\nAgreement Preamble\nAlliance Manager Section 2.1\nApplicable Reduction Percentage Section 9.3(c)(ii)\nAsset Transfer Section 1.12\nBase Net Sales Section 9.3(c)(ii)\nClosing Conditions Section 13.6\nCo-Promotion  Agreement Section 8.7(c)\nCo-Promotion  Option Section 8.7(a)\nCo-Promotion  Product Section 8.7(a)\nCo-Promotion  Territory Section 8.7(a)\nCombination Therapy Section 5.3(a)\nCommercialization Plan Section 8.2\nConfidentiality Agreement Section 15.9\nCREATE Act Section 10.3\nData Package Section 5.2(c)\nDevelopment Candidate Section 4.3\nDevelopment Budget Section 5.2(a)\nDevelopment Plan Section 5.2(a)\n[***] Section 5.2(b)\nDisclosing Party Section 11.1(a)\nDispute Section 15.6(a)\nDistributor Section 8.3\nEffective Date Section 3.8\nExecution Date Preamble\n\nof such Calendar Quarter, each Party will provide to the JRDC a detailed expense report in form approved by the JRDC with respect to the Research and\nDevelopment Costs incurred by or on behalf of such Party during such Calendar Quarter consistent with the previous sentence (including, if requested\nby Sanofi in writing, copies of receipts or invoices from Third Parties for all RevMed R&D Out-of-Pocket  Costs). The Party that incurs more than its share\nof the total Research and Development Costs during any such Calendar Quarter shall deliver an invoice to the other Party for an amount of cash\nsufficient to reconcile to the invoicing Party\u2019s agreed percentage of Research and Development Costs. Such other Party will reimburse the invoicing Party\nin Dollars all undisputed amounts within such expense reports under this Section 4.5 in accordance with Section 9.5 mutatis mutandis .\nArticle V.\nDEVELOPMENT",
  "parties": "applicable) to the other Party as follows:\n(a) It is a company or corporation duly organized, validly existing, and in good standing under the laws of the jurisdiction in which it is\nincorporated, and has the full right, power and authority to enter into this Agreement, to perform its obligations hereunder.\n(b) (i) This Agreement has been duly executed by it and is legally binding upon it, enforceable in accordance with its terms, (ii) it has taken all\nnecessary corporate action on its part required to authorize the execution and delivery of this Agreement and, (iii) this Agreement, and the performance of\nits obligations hereunder, do not conflict with any agreement, instrument or understanding, oral or written, to which it is a party or by which it may be\nbound, nor violate any material law or regulation of any court, governmental body or administrative or other agency having jurisdiction over it.\n\nAgreement or the Correspondence\u037e (iii) any Ancillary Agreement\u037e and (iv) any exhibit or schedule of any Ancillary Agreement.\n15.11  Headings . The captions to the several Articles, Sections, subsections and Exhibits hereof are not a part of this Agreement, but are merely for\nconvenience to assist in locating and reading the several Articles, Sections, subsections and Exhibits hereof.\n15.12  Independent Contractors . It is expressly agreed that RevMed and Sanofi shall be independent contractors and that the relationship between\nthe two Parties shall not constitute a partnership, joint venture or agency. Neither RevMed nor Sanofi shall have the authority to make any statements,\nrepresentations or commitments of any kind, or to take any action, which shall be binding on the other Party, without the prior written consent of the\nother Party.\n\nthe terms and conditions of this Agreement\u037e or (c) determine any issue in a manner that would conflict with the express terms and conditions of this\nAgreement.\n2.8 Committee Membership and Meetings .\n(a) Committee Members . The initial members of each Party on each Committee (other than the JCC) as of the Effective Date are set forth in Exhibit F\nof the Correspondence. Each Party may replace its representatives on any Committee by written notice to the other Party. Each Committee representative\nshall have appropriate knowledge and expertise and sufficient seniority within the applicable Party to make decisions arising within the scope of the\napplicable Committee\u2019s responsibilities. A particular individual may serve as a Party\u2019s representative on more than one Committee, provided that such\nindividual satisfies the requirements of the preceding sentence for each applicable Committee. Each Party shall appoint one of its representatives on each\n\nobligations with respect to the Research, Development, Manufacture and Commercialization of any Product, and (iii) RevMed shall not, without the prior\nwritten approval of Sanofi, otherwise subcontract to Third Parties the performance of RevMed\u2019s tasks and obligations with respect to the Research,\nDevelopment, Manufacture and Commercialization of any Product. If Sanofi approves a Third Party subcontractor of RevMed following the Effective\nDate, or such Third Party is named in the Research Plan or the Development Plan, then RevMed, unless otherwise explicitly waived by the Sanofi Alliance\nManager, shall enter into a written agreement with such Third Party substantially in a form approved by Sanofi and such Third Party shall be deemed a\nPermitted Subcontractor or Researcher under this Agreement. Each Party shall remain liable for any action or failure to act by its Affiliates, Sublicensees",
  "key_terms": "13.6 Closing Conditions . The obligations of each Party to consummate the transactions contemplated by this Agreement and the Ancillary\nAgreements (the \u201c Contemplated Transactions \u201d) is subject to the fulfillment, or, to the extent permitted by Applicable Law, waiver by such Party, of each\nof the following conditions (collectively, the \u201c Closing Conditions \u201d):\n(a) The representations and warranties of the other Party contained in this Agreement (i) that are not qualified by materiality, material adverse\neffect, substantial compliance or similar materiality qualifier will be true and correct in all material respects both when made and at the closing with the\nsame force and effect as if made on the Effective Date and (ii) that are qualified by materiality, material adverse effect, substantial compliance or similar\nmateriality qualifier will be true and correct in all respects both when made and at the closing with the same force and effect as if made on the Effective\n\napplicable) to the other Party as follows:\n(a) It is a company or corporation duly organized, validly existing, and in good standing under the laws of the jurisdiction in which it is\nincorporated, and has the full right, power and authority to enter into this Agreement, to perform its obligations hereunder.\n(b) (i) This Agreement has been duly executed by it and is legally binding upon it, enforceable in accordance with its terms, (ii) it has taken all\nnecessary corporate action on its part required to authorize the execution and delivery of this Agreement and, (iii) this Agreement, and the performance of\nits obligations hereunder, do not conflict with any agreement, instrument or understanding, oral or written, to which it is a party or by which it may be\nbound, nor violate any material law or regulation of any court, governmental body or administrative or other agency having jurisdiction over it.\n\n1.131  In addition to the foregoing definitions, the following table identifies the location of the following definitions set forth in various other\nSections of, or Exhibits to, the Agreement:\nDefined Term Section\nAcquiror Section 15.2(a)\nAgreement Preamble\nAlliance Manager Section 2.1\nApplicable Reduction Percentage Section 9.3(c)(ii)\nAsset Transfer Section 1.12\nBase Net Sales Section 9.3(c)(ii)\nClosing Conditions Section 13.6\nCo-Promotion  Agreement Section 8.7(c)\nCo-Promotion  Option Section 8.7(a)\nCo-Promotion  Product Section 8.7(a)\nCo-Promotion  Territory Section 8.7(a)\nCombination Therapy Section 5.3(a)\nCommercialization Plan Section 8.2\nConfidentiality Agreement Section 15.9\nCREATE Act Section 10.3\nData Package Section 5.2(c)\nDevelopment Candidate Section 4.3\nDevelopment Budget Section 5.2(a)\nDevelopment Plan Section 5.2(a)\n[***] Section 5.2(b)\nDisclosing Party Section 11.1(a)\nDispute Section 15.6(a)\nDistributor Section 8.3\nEffective Date Section 3.8\nExecution Date Preamble\n\n(ii) as provided in this Section 11.5 or as otherwise provided in this Agreement or any Ancillary Agreement or with the prior express written permission of\nthe other Party, except as may be required by Applicable Law.\n(b) If a Party is required by Applicable Law, rule or regulation to make a securities filing relating to the signing or effectiveness of this Agreement,\nor to the terms of this Agreement, with the appropriate Governmental Authorities (including the U.S. Securities and Exchange Commission, and any\nsecurities exchange on which securities of such Party are listed), then the Party under such requirement will prepare a draft of such securities filing for\nreview and comment by the other Party. If such securities filing includes the disclosure of this Agreement and its terms, the Party under such disclosure\nobligation will submit a confidential treatment request and a proposed redacted version of this Agreement as part of such draft. Such draft securities"
}